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Motor fluctuations and non-response to carbidopa-levodopa (Sinemet) therapy are major
problems in the long-term management ofParkinson's disease. Levodopa manipulation, addition
ofadjuvants, and drug holidays are often unsuccessful. Others have shown that the clinical state
of stabilized Parkinsonians can be reversed with intravenous administration of large neutral
amino acids. Reasoning that dietary protein might precipitate motor oscillations and non-
response, a low-protein daytime diet (7 g) was offered to fifteen patients. Eighty-six percent of
this sample demonstrated immediate sensitivity toSinemet. Whileon a low-protein diet, patients'
clinical function was predominantly choreatic. Eight patients required a 10-60 percent reduction
in their daily levodopa dose in order to minimize this choreatic tendency. Discontinuation of
adjuvants did not compromise motor independence. Conversely, while on a high-protein diet (160
g), patients were predominantly immobile with markedly elevated plasma amino acid and
levodopa levels.
Consequently, elimination of dietary protein from breakfast and lunch can offer an effective
and easily modified method for the ameloriation of motor fluctuations and non-response to
Sinemet in Parkinson's disease during working hours.
INTRODUCTION
The development of random, daily motor fluctuations and non-response to carbi-
dopa-levodopa (Sinemet) therapy are major problems in the long-term management of
patients with Parkinson's disease. It is reported that up to eighty-four percent of
patients treated with Sinemet will experience response fluctuations within ten years of
initiating therapy [1]. A variety of approaches for optimizing clinical management,
such as readjustment of levodopa, addition of costly adjuvant prescriptions, and/or
hospitalization for drug holidays have met with only varying degrees of success. Nutt
and others have reported that theclinical state ofParkinsonian patients that have been
stabilized by continuous levodopa infusion could be reversed by intravenous adminis-
tration ofcertain large neutral amino acids or by having patients consume meals high
in protein content [2,3,4]. Reasoning that dietary protein mightantagonize the clinical
effectiveness of levodopa, a low-protein diet was offered to two groups of Parkinson's
patients: those patients with daily motor oscillations and those with apparent non-
response to carbidopa-levodopa therapy.
METHODOLOGY
Adults referred to the Yale Parkinson's Clinic with idiopathic Parkinson's diseaseof
more than three years' duration, who were experiencing unpredictable motor fluctua-
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TABLE 1
Clinical Status of Parkinson Patients on Low-Protein Diet
Fluctuators Non-Responders
Sex 4 males, 4 females 5 males, 2 females
Mean age (years) 56 (range: 45-68 years) 66 (range: 64-69 years)
Mean duration ofParkinson's 12 years (range: 5-20 years) 8 years (range: 3-12 years)
Mean duration of fluctuations 3 years (range: 2-6 years)
Mean L-Dopa requirement for 866 mg (range: 450-1,750 mg)
best function
On regular diet 1,497 mg (range: 575-2,000 mg)
On low-protein diet 959 mg (range: 300-500 mg) 828 mg (range: 400-1,500 mg)
Mean Parkinson disability score
On regular diet 33 (range: 18-50)
On low-protein diet 16 (range: 2-34)*
*Six ofseven demonstrated increased sensitivity to levodopa-carbidopa.
tions or non-response to carbidopa-levodopa therapy, were invited to participate in this
clinical investigation. Some but not all patients were admitted to the Clinical Research
Center at Yale-New Haven Hospital for a brief inpatient stay. While hospitalized,
patients received differing isocaloric oral diets. On one day ofhospitalization, patients
received a low-protein diet containing 7 g of protein between 8:00 A.M. and 4:00 P.M.
The next day, they received a high-protein diet containing 160 g of protein between
8:00 A.M. and 4:00 P.M. Patients served as their own controls. Thedosage and timing of
medication administration were held constant. The only variable that was altered was
the amount of dietary protein. Each day from 8:00 A.M. to 4:00 P.M. hourly
determinations of plasma levodopa and neutral aromatic amino acids (phenylalanine,
tyrosine, leucine, isoleucine, valine, tryptophan, and methionine) were obtained.
Concomitant clinical assessment using the Northwestern Disability [5] and AIMS [6]
Dyskinesia Scale was documented on videotape.
RESULTS
Fifteen patients have followed this low-protein diet. Eight patients suffered with
crippling daily motor fluctuations in response to carbidopa-levodopa therapy (Table
1). There were four males and four females, ranging in age from 45-68 years of age,
with a mean age of 56. They had Parkinson's disease of 5-20 years' duration, with a
mean of 12 years. These patients had experienced fluctuations for two to six years,
during which time they had not responded to changes in their dose schedule, adjuvants,
or, in two cases, drug holidays. Seven patients (86 percent) derived immediate clinical
benefit from a low-protein diet, while one patient (14 percent) did not. Six patients (75
percent) required a 10-60 percent reduction in their total daily levodopa dose in order
to avoid chorea. The mean reduction in total daily levodopa dose was 39 percent. No
patient required an increase in levodopa, while all adjuvant therapy was successfully
discontinued in three patients (38 percent). The meandaily levodopa dosage while on a
regular diet was 1,497 mg, whereas the mean daily levodopa requirement while on the
low-protein diet was 959 mg (Table 1).
The second subsetofthis study sample was composed ofseven patients who;had been
categorized as non-responders to carbidopa-levodopa therapy (Table 1). There were
five males and two females, ranging in age from 64-69 years, with a mean age of 66.
They had Parkinson's disease of 3-12 years' duration, with a mean ofeight years. Just
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FIG. l. This represents the hourly clinical condition ofone Parkinson
patient who had experienced marked fluctuations. On both days of the
study the amount of 1-dopa-carbidopa was held constant. One 25/l00
tablet was administered every two hours, starting at 8:00 A.M. While on
a low-protein diet, he consumed 7 g protein diet between 8:00 A.M. and
4:00 P.M. While on the high-protein diet, he consumed l160g protein diet
during the same hours. Dyskinesia was scored using the AIMS Scale.
The higher numbers on the y axis represent greater dyskinesia. Parkin-
sonism was scored using the Northwestern scale. Greater negativity on
the y axis represents more severe Parkinsonism. A score of 0 on the y
axis represents normal function.
prior tostarting thelow-protein diet, they werereceiving a mean of866 mgoflevodopa
per day without significant clinical benefit. While on a low-protein diet, patients
required a mean of 828 mg perday (Table 1). Six patients (86 percent) demonstrated
immediate sensitivity to Sinemet, while one patient did not. Two patients (29 percent)
required a slight reduction in their total levodopa daily requirement by I11 percent and
14 percent, respectively, in order to avoid chorea. Three patients (43 percent) were
maintained on their same daily levodopa dose, and two of these patients experienced
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clinical improvement. One patient was improved by restarting carbidopa-levodopa at a
dosage that had previously been "ineffective," and only one patient required an
increase in the levodopa dose. Discontinuation oflevodopa agonistsdid notcompromise
motor improvement. Northwestern Disability score before the introduction of a
low-protein diet ranged between 18-50, with a mean disability of 33. Northwestern
Disability score while on a low-protein diet ranged between 2-34, with a mean of 16
(Table 1). While on a low-protein diet, there was a mean improvement ofthedisability
score of 17 points, and all but one patient were receiving less or the same amount of
anti-Parkinson medication.
While on the low-protein diet, both groups (the fluctuators and the non-responders)
were predominantly choreatic (Fig. 1). This result correlated with depressed plasma
amino acid levels (Fig. 2). Conversely, while on a high-protein diet, patients were
predominantly immobile and had markedly elevated plasma amino acid levels.
Levodopa levels were higher in the immobile patients when they received the
protein-elevated diet (Fig. 3).
DISCUSSION
Fluctuations and non-response to carbidopa-levodopa therapy during daytime hours
can be markedly ameliorated by eliminating dietary protein from breakfast and lunch.
This method has permitted patients to achieve a smooth response to therapy with
markedly improved global function and sensitivity to Sinemet. In the management of
motor oscillations, the low-protein daytime diet necessitated a reduction in total
levodopa dose and discontinuation of adjuvant therapy in order to avoid dyskinetic
toxicitywhile preserving mobility. Theachievement and maintenance ofoptimal motor
function endured until the evening meal, after which most patients became immobile.
Non-responders were made responsive to Sinemet merely by eliminating dietary
protein until the evening meal. To date, the length of follow-up through the Yale
Parkinson's Clinic is one to ten months. All patients have remained healthy. All
patients have remained at or above ideal body weight, though some have lost weight on
this diet. The effective dose of levodopa in both fluctuators and non-responders was
comparable, in that it ranged around 850 and 950 mg perday. In controlled studies, the
136PARKINSON'S AND DIET 137
levodopa plasma concentrations were higher in the immobile patients who were
receiving high-protein meals. This finding may be the result of reduced transport of
levodopa into the brain caused by markedly elevated plasma amino acid levels.
Though the explanation for the clinical phenomenon is conjectural and depends
upon data compared in single-day consecutive studies, it has become clear that protein
antagonizes the clinical effectiveness of Sinemet. A low-protein dietary regimen may
offer an important therapeutic device for the control of fluctuations and non-response
to Sinemet therapy in Parkinson's disease.
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